• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Concludes the Clinical Data Summary Pilot Program

FDA Concludes the Clinical Data Summary Pilot Program

March 29, 2020

The FDA has called a halt to its Clinical Data Summary (CDS) pilot program after two years and limited results, saying it will shift its focus to a new application review process that would allow more transparency and access to data from trials of approved drugs.

The agency launched the voluntary CDS pilot in January 2018 to evaluate whether sharing data from FDA-approved drugs’ clinical study reports would be beneficial to sponsors, researchers and the public. After selecting nine sponsors to participate in the pilot, the agency was able to release data from only one approved drug — Janssen’s Erleada (apalutamide) — in March 2018.

Then in June 2019, the FDA announced it was closing enrollment in the pilot and beginning work on the interdisciplinary review program, which the agency says has more potential for data-sharing by involving more parties in the evaluation of drug applications rather than releasing sponsor’s trial summaries. Center for Drug Evaluation and Research Director Janet Woodcock said last week, however, that the FDA may consider sharing specific portions of clinical data summaries as part of the new review process.

Despite its limited success, the FDA says the CDS pilot has helped the agency identify possible approaches to global sharing of clinical trial data, including an independently run international library of data that would allow sponsors to contribute results voluntarily in an anonymous and standardized format.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing